间充质干细胞体外扩增联合自体外周血造血干细胞移植治疗恶性血液病  

Expansion of Mesenchymal Stem Cells(MSCs) in Vitro and Coinfusion of Autologous Peripheral Blood Stem Cells and Expanded MSCs in Hematologic Malignancies

作　　者：孟丽娟[1] 李建勇[1] 陆化[1] 吴汉新[1] 吴冠宇[1] 朱雨[1] 刘澎[1] 黄峻[1] 

机构地区：[1]南京医科大学附属第一医院血液科,江苏南京210029

出　　处：《苏州大学学报（医学版）》2005年第2期252-255,共4页Suzhou University Journal of Medical Science

基　　金：江苏省基础计划重大招标项目 (160DC0 40 1);江苏省科技厅社会发展基金 (160DB0 3 0 1);江苏省卫生厅医学科技发展基金(H2 0 0 3 13 )资助

摘　　要：目的　探讨体外培养扩增临床规模的人骨髓间充质干细胞(MSCs)的可行性及其联合自体造血干细胞(APBSCs)移植治疗恶性血液病的可行性、安全性和对造血重建的影响。方法　骨髓单个核细胞(MNC)来自12例正常人及恶性血液病患者,采用无血清培养基体外培养人骨髓间充质干细胞(MSCs)。MSCs联合APBSCs移植治疗4例恶性血液病。结果　能够从所有2 6 .3±8.8ml骨髓样本中提取MSCs,其中10例成功扩增。4例患者接受扩增后MSCs联合APBSCs输注。MSCs输注无明显不良反应。中性粒细胞≥0 .5×10 9/L和血小板≥2 0×10 9/L中位时间分别为9(8～11)d和8.3(7～10 )d。结论　应用无血清培养体系可培养扩增临床规模的人MSCs。MSCs联合APBSCs共移植安全可行。快速的造血恢复提示在清髓性治疗后输注MSCs可促进造血。Objective To explore clinical scale expansion of human bone marrow mesenchymal stem cells (MSCs) and investigate the feasibility, safety, and hematopoietic reconstitution effects of culture-expanded MSCs in patients with hematologic malignancies receiving coinfusion of autologous peripheral blood stem cells (APBSCs) and expanded MSCs. Methods Bone marrow mononuclear cells (MNCs) were obtained from 12 healthy donors or patients with hematologic malignancies and MSCs were expanded in vitro in Mesencult serum free media. Four patients were given APBSCs plus culture-expanded MSC infusion. Results Human MSCs were isolated from a of 26.3±8.8 ml (mean±SD) bone marrow aspirate from all subjects. Ten of the samples have been successfully expanded. Four patients were infused with expanded autologous MSCs as well as APBSCs. There were no toxicities related to the infusion of MSCs. Median time to achieve neutrophil counts greater than 0.5×109/L and platelet counts greater than 20×109/L were 9 days (ranging 8 to 11 days) and 8.3 days (range, 7 to 10 days), respectively. Conclusion Mesencult serum free media is able to generate sufficient MSCs for clinical purpose and cotransplantation of MSCs and APBSCs is feasible and safe. Rapid hematopoietic recovery suggests that MSCs infusion after myeloablative therapy can have a positive impact on hematopoiesis.

关 键 词：间充质干细胞 自体外周血造血干细胞 联合移植 恶性血液病 

分 类 号：R552[医药卫生—血液循环系统疾病]